Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Millennium Gets Priority Review for Velcade | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Millennium Gets Priority Review for Velcade

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium’s Velcade was granted priority review from the FDA for patients with newly diagnosed multiple myeloma (MM). The sNDA for this indication included data from the Phase III VISTA study, a large, international trial, comparing a Velcade based regimen to a traditional standard of care.

Priority review is granted for a treatment that addresses an unmet medical need and demonstrates an improvement over existing therapies. The FDA expedites the approval process for these applications from ten to six months.

The VISTA trial included 682 patients with newly diagnosed MM ineligible for stem cell transplantation. The trial compared Velcade, melphalan and prednisone (VcMP) to the standard regimen of melphalan and prednisone (MP) alone. VcMP achieved a statistically significant improvement across all efficacy endpoints, including complete remission (CR) rates, time-to-disease progression (TTP) and survival (progression-free survival and overall survival). VcMP demonstrated an immunofixation-negative CR rate of 35% compared to 5% in the MP arm.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters